Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (231-240 of 333) with videos related to

Pageof 34
Sort By:
European Journal of Human Genetics : EJHG|November 14, 2013
Common genetic variants do not associate with CAD in familial hypercholesterolemiaErik P A van Iperen, Suthesh Sivapalaratnam, S Matthijs Boekholdt, et al.
European Heart Journal|September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaJohn J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
Journal of Lipid Research|May 8, 2013
In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1Adriaan G Holleboom, Lily Jakulj, Remco Franssen, et al.
American Heart Journal|September 11, 2020
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and designDonna H Ryan, Ildiko Lingvay, Helen M Colhoun, et al.
European Heart Journal|March 4, 2014
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcomeBarbara Sjouke, D Meeike Kusters, Iris Kindt, et al.
Diabetes, Obesity & Metabolism|March 22, 2023
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trialDarren K McGuire, Rodica P Busui, John Deanfield, et al.
Obesity (Silver Spring, Md.)|December 11, 2022
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristicsIldiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, et al.
European Journal of Human Genetics : EJHG|April 23, 2015
A rare variant in MCF2L identified using exclusion linkage in a pedigree with premature atherosclerosisStephanie Maiwald, Mahdi M Motazacker, Julian C van Capelleveen, et al.
Journal of Lipid Research|December 29, 2006
Cholesteryl ester transfer protein and hyperalphalipoproteinemia in CaucasiansWim A van der Steeg, G Kees Hovingh, Anke H E M Klerkx, et al.
Atherosclerosis|March 28, 2026
Traditional cardiovascular risk factors and their association with atherosclerotic cardiovascular disease in homozygous familial hypercholesterolemia: A cross-sectional analysis from the HICC registryWillemijn Am Schonck, G Kees Hovingh, Dirk J Blom, et al.
Pageof 34

Showing results (231-240 of 333) with videos related to

Sort By:
Pageof 34
European Journal of Human Genetics : EJHG|November 14, 2013
Common genetic variants do not associate with CAD in familial hypercholesterolemiaErik P A van Iperen, Suthesh Sivapalaratnam, S Matthijs Boekholdt, et al.
European Heart Journal|September 3, 2015
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaJohn J P Kastelein, Henry N Ginsberg, Gisle Langslet, et al.
Journal of Lipid Research|May 8, 2013
In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1Adriaan G Holleboom, Lily Jakulj, Remco Franssen, et al.
American Heart Journal|September 11, 2020
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and designDonna H Ryan, Ildiko Lingvay, Helen M Colhoun, et al.
European Heart Journal|March 4, 2014
Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcomeBarbara Sjouke, D Meeike Kusters, Iris Kindt, et al.
Diabetes, Obesity & Metabolism|March 22, 2023
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trialDarren K McGuire, Rodica P Busui, John Deanfield, et al.
Obesity (Silver Spring, Md.)|December 11, 2022
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristicsIldiko Lingvay, Kirstine Brown-Frandsen, Helen M Colhoun, et al.
European Journal of Human Genetics : EJHG|April 23, 2015
A rare variant in MCF2L identified using exclusion linkage in a pedigree with premature atherosclerosisStephanie Maiwald, Mahdi M Motazacker, Julian C van Capelleveen, et al.
Journal of Lipid Research|December 29, 2006
Cholesteryl ester transfer protein and hyperalphalipoproteinemia in CaucasiansWim A van der Steeg, G Kees Hovingh, Anke H E M Klerkx, et al.
Atherosclerosis|March 28, 2026
Traditional cardiovascular risk factors and their association with atherosclerotic cardiovascular disease in homozygous familial hypercholesterolemia: A cross-sectional analysis from the HICC registryWillemijn Am Schonck, G Kees Hovingh, Dirk J Blom, et al.
Pageof 34